You are here

Article Text

Article menu
Download PDFPDF
Miscellaneous
Is adjuvant chemotherapy for non-small cell lung cancer here to stay?
  1. T J Warke
  1. Consultant Respiratory Physician, Royal Victoria Hospital, Belfast, UK; tim@dsl.pipex.com

https://doi.org/10.1136/thx.2005.la0167

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    ▴ Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer. N Engl J Med2005;352:2589–97
    OpenUrlCrossRefPubMedWeb of Science

    In this study patients with completely resected stage IB or stage II non-small cell lung cancer were randomised to either adjuvant chemotherapy with vinorelbine and cisplatin (n = 242) or to observation (n = 240). The primary end point was overall median survival which was significantly prolonged in the chemotherapy group (94 v 73 …

    View Full Text